HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.

AbstractINTRODUCTION:
Several pretreatment factors have been reported to be useful in predicting patients with a high probability for a sustained response to IFN-alpha treatment, however, predictors of the efficacy of interferon-beta treatment in chronic hepatitis C have not been fully assessed.
MATERIAL AND METHODS:
To clarify this issue, a prospective study of 52 patients with chronic hepatitis C was conducted. Patients were treated with human natural interferon-beta by drip infusion at doses of 6 MU/day for 8 weeks. The following characteristics were compared between patients with sustained response (SR) and no response (NR): gender, age, source of HCV infection, mean pretreatment serum ALT levels, liver histology, pretreatment serum HCV-RNA levels and HCV genotype.
RESULTS:
Seventeen of 52 patients (32.7%) demonstrated SR. The proportion of patients with undetectable HCV-RNA levels determined by branched DNA assay (< 0.5 x 10(6) eq/ml) was higher in patients with SR than in those with NR (88.2% vs. 22.9%; p = 0.0001). Pretreatment HCV RNA levels determined by multicyclic reverse transcriptase polymerase chain reaction were lower in patients with SR than in those with NR (10(5.1 +/- 1.5) vs. 10(7.1 +/- 1.3) copies/ml; p = 0.0001). The rate of SR was higher in patients with genotype 2a or 2b than in genotype 1b (43.8% vs. 15.0%; p = 0.0382). Multivariate stepwise logistic regression analysis showed that a younger age and low pretreatment serum levels of HCV RNA were independent predictors of SR to treatment. This prospective study demonstrated that a younger age, low pretreatment viral load and HCV genotype 2a or 2b were factors influencing the SR to interferon-beta treatment, but a younger age and low pretreatment viral load were most important predictors of the efficacy of the treatment.
AuthorsT Fukutomi, M Fukutomi, M Iwao, H Watanabe, Y Tanabe, K Hiroshige, N Kinukawa, M Nakamuta, H Nawata
JournalMedical science monitor : international medical journal of experimental and clinical research (Med Sci Monit) 2000 Jul-Aug Vol. 6 Issue 4 Pg. 692-8 ISSN: 1234-1010 [Print] Poland
PMID11208393 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • RNA, Viral
  • Interferon-beta
Topics
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents (administration & dosage, adverse effects, therapeutic use)
  • Female
  • Genotype
  • Hepacivirus (genetics, isolation & purification)
  • Hepatitis C, Chronic (drug therapy, virology)
  • Humans
  • Infusions, Intravenous
  • Interferon-beta (administration & dosage, adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prospective Studies
  • RNA, Viral (blood, genetics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: